SCHEMBL30540502

SCHEMBL30540502

CC(C)CNCc1cc(C(=O)O)nc2cc[nH]c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 1/20 0.38
▸ TPO P07202 1/20 0.38
▸ CD38 P28907 3/20 0.34
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ IGFBP5 P24593 2/20 0.33
▸ IGFBP3 P17936 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KDM5A P29375 1/20 0.32
▸ KDM5B Q9UGL1 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ ADRB1 P08588 1/20 0.31
▸ CXCR2 P25025 1/20 0.31
▸ BCHE P06276 1/20 0.31
▸ HCAR3 P49019 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30540661 0.83 CD38 (0.34) CD38KMT2ATDP1IGFBP5IGFBP3
SCHEMBL25349795 0.83 CD38 (0.34) CD38KMT2ATDP1IGFBP5IGFBP3
SCHEMBL30540543 0.79 MPO (0.41) MPOTPOCD38MEN1KMT2A
SCHEMBL30540576 0.78 KAT2B (0.36) CD38ALDH1A1
SCHEMBL30540594 0.77 CD38 (0.36) CD38IGFBP5IGFBP3ALDH1A1KDM4E
SCHEMBL30540630 0.77 MPO (0.36) MPOTPO
SCHEMBL25349613 0.76 GPR35 (0.36) MEN1KMT2AALDH1A1KDM5A
SCHEMBL25346022 0.76 PNP (0.33) —
SCHEMBL30540566 0.75 CD38 (0.35) CD38IGFBP5IGFBP3ALDH1A1KDM4E
SCHEMBL30577619 0.75 CD38 (0.33) CD38IGFBP5IGFBP3ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 — — US disclosed
EP-4476219-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2024-12-18 — — EP disclosed
CN-118696043-A Heterocyclic compounds, compositions thereof and methods of treatment therewith 百济神州有限公司 2024-09-24 — — CN disclosed
WO-2023151641-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 — — WO disclosed
WO-2023151636-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG MPO 19/4885TPO 1719/4885CD38 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback